Search

everythinglearnresearchcommunity

for

Search:↓

Blood tests for tumor cells could improve prostate cancer diagnosis and treatment; hair loss severity linked to a gene affecting prostate conditions.

New drugs and therapies targeting specific pathways show promise in treating advanced prostate cancer.

CEC levels may be a useful marker for predicting prostate cancer progression.

The document concludes that a new biosensor can efficiently detect prostate cancer cells and that standardized referrals help find significant cancers effectively.

Gene variation affects prostate issues and hair loss.

Certain HSD3B1 gene types are linked to worse prostate cancer outcomes and affect treatment response and other health conditions.

Male pattern baldness does not cause an increased risk of prostate cancer.

Testosterone may have a dual role in COVID-19, potentially worsening outcomes in men, and testosterone therapy could help some patients, but more research is needed.

Chemotherapy with docetaxel can cause painful nail and skin side effects that may lead to stopping treatment.

Docetaxel often causes hair loss, with limited effective treatments and no cure for permanent hair loss.

Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

Combining flutamide and finasteride can reduce prostate weight and tumor growth, potentially benefiting treatments needing optimal DHT inhibition.

New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.

Finasteride doesn't improve survival in LNCaP tumor model during off-cycle of therapy.

Androgenetic alopecia negatively affects self-esteem and daily stress, especially in young men.

Certain inhibitors can potentially treat prostate cancer and other hormone-dependent conditions by controlling sex hormone levels in cells.

Dehydroepiandrosterone (DHEA) is a prohormone important for producing sex steroids and has potential health benefits.

The number of advanced breast cancer cases in women under 40 has increased, but the overall numbers are still low.

Plant-based compounds might be a promising alternative for prostate cancer treatment with fewer side effects.

Mutations in certain receptors can cause diseases and offer new treatment options.

Advancements in male reproductive medicine are ongoing, but more research and improved treatments are needed in several areas.

Minoxidil can reduce functions related to androgen receptors.

Sex hormones might influence bladder cancer development, and aromatase inhibitors could increase risk in postmenopausal women.

Using finasteride with TIP extends time off period for prostate cancer patients.

Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.

Too much AKR1C3 enzyme causes resistance to finasteride by increasing testosterone.

Low testosterone in men is a risk factor for a specific heart rhythm issue, and testosterone treatment may help prevent it.

The skin's ability to produce hormones is linked to various skin conditions, and better understanding this process could lead to new treatments.